TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1906363

Group type: EXPERIMENTAL
Intervention: RU486 (Mifepristone) and Misoprostol (orally active PGE1 synthetic derivative)
Number of subjects: 100

Group type: COMPARATOR
Intervention: RU486 (Mifepristone) and Sulprostone (intramuscularly injected prostaglandin)
Number of subjects: 100
Study: 6396248

Group type: EXPERIMENTAL
Intervention: 10% crotamiton lotion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study: 30813955

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 54
Study: 30845291

Group type: EXPERIMENTAL
Intervention: SRP + Amoxicillin + Metronidazole, each 500 mg, three times daily, for seven days (test group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SRP + placebo for seven days (control group)
Number of subjects: 16
Study: 26685701

Group type: EXPERIMENTAL
Intervention: Vilazodone (up to 40 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 76
Study: 24628408

Group type: EXPERIMENTAL
Intervention: Face Mask (FM) treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Face Mask (FM) treatment with Rapid Maxillary Expansion (RME)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 32
Study: 22931974

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 59

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 59
Study: 21179724

Group type: EXPERIMENTAL
Intervention: Chinese drugs for benefiting‐qi, activating‐blood, dissolving phlegm and removing‐toxin (CDs) combined with basic therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Basic therapy only (Control)
Number of subjects: 56
Study: 17514701

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with local anaesthetic
Number of subjects: 16
Study: 15620437

Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day for one year
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (age, sex, BMI matched)
Number of subjects: 106
Study: 11879860

Group type: EXPERIMENTAL
Intervention: Intensive 3-day communication skills training course
Number of subjects: 160

Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 10206573

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Enucleation
Number of subjects: 147
Study: 7615288

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 65
Study: 2297261

Group type: EXPERIMENTAL
Intervention: Fibrin glue spray (2 ml applied before thoracotomy closure)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 28
Study: 832923

Group type: EXPERIMENTAL
Intervention: Hypnotic subjects (Ss)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Task motivated Ss
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Ss
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypnotic Ss with high suggestibility
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypnotic Ss responding to difficult task aspects
Number of subjects: 90
Study: 31488259

Group type: EXPERIMENTAL
Intervention: Steroids (first line treatment)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rituximab (monotherapy or in association with steroids)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination of steroids with rituximab
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 93
Study: 30732945

Group type: EXPERIMENTAL
Intervention: FIPELS technique flap design
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 35
Study: 26746184

Group type: EXPERIMENTAL
Intervention: Intensive SBP management (<140 mm Hg)
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Guideline-based SBP management (<180 mm Hg)
Number of subjects: 1310
Study: 25730283

Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus argon plasma coagulation (APC)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus soft coagulation using hemostatic forceps (HFSC)
Number of subjects: 276
Study: 23523332

Group type: EXPERIMENTAL
Intervention: Injections during labor
Number of subjects: 22352
Study: 21474498

Group type: EXPERIMENTAL
Intervention: internet-based monitoring system (internet strategy)
Number of subjects: 95

Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 95
Study: 19281920

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 80
Study: 17084960

Group type: EXPERIMENTAL
Intervention: alpha‐blocker
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: triple therapy (alpha‐blocker, anti‐inflammatory, and muscle relaxant)
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 15276394

Group type: EXPERIMENTAL
Intervention: Darusentan 10 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Darusentan 25 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Darusentan 50 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Darusentan 100 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Darusentan 300 mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 11352981

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3‐week n‐3 PUFA‐enriched diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mM of eicosapentaenoic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mM of docosahexaenoic acid (DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA
Number of subjects: 0
Study: 9456068

Group type: EXPERIMENTAL
Intervention: 300 mg of 2,3 dimercapto‐1‐propane sulfonic acid (DMPS)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Amalgam removal
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 348
Study: 8197927

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3286547

Group type: EXPERIMENTAL
Intervention: Systemic alpha-interferon (10 million units subcutaneously daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Systemic acyclovir (5 mg/kg body weight intravenously thrice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Systemic alpha-interferon
Number of subjects: 64

Group type: COMPARATOR
Intervention: Systemic acyclovir
Number of subjects: 64
Study: 31846024

Group type: EXPERIMENTAL
Intervention: Flags approach-based educational intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 63
Study: 29748628

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28012835

Group type: EXPERIMENTAL
Intervention: low‐flu/val (10/20mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 26412349

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone without chemotherapy (for recurrence score of 0 to 10)
Number of subjects: 1626
Study: 23679351

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily (Arm A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily, 14-days-on/7-days-off (Arm B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily, 5-days-on/2-days-off (Arm C)
Number of subjects: 49
Study: 20734448

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 52
Study: 19180923

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: remifentanil 3 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: vecuronium bromide 0.1 mg/kg (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (I, II, III)
Number of subjects: 120
Study: 16635694

Group type: EXPERIMENTAL
Intervention: Levalbuterol (Lev) 1.25 mg
Number of subjects: 627

Group type: COMPARATOR
Intervention: Racemic albuterol (Rac) 2.5 mg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Levalbuterol (Lev)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Racemic albuterol (Rac)
Number of subjects: 627
Study: 12786700

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (Restylane)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bovine collagen (Zyplast)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 138
Study: 10982117

Group type: EXPERIMENTAL
Intervention: Interactive video plus a booklet
Number of subjects: 393

Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 393
Study: 8973725

Group type: EXPERIMENTAL
Intervention: anti-H2 treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 1729971

Group type: EXPERIMENTAL
Intervention: Dantrolene Sodium (Dantrium), 200 mg per day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6385051

Group type: EXPERIMENTAL
Intervention: Relaxation-only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N2O only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation with N2O
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air-control
Number of subjects: 0
Study: 31025470

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Rehabilitation (CBR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 39
Study: 28752800

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) for 24 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waitlist group (habitual lifestyle for 24 weeks)
Number of subjects: 35
Study: 26948290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 24953493

Group type: EXPERIMENTAL
Intervention: Contralateral symptomatic plaques
Number of subjects: 39

Group type: COMPARATOR
Intervention: Symptomatic plaques
Number of subjects: 39

Group type: COMPARATOR
Intervention: Asymptomatic plaques
Number of subjects: 39
Study: 22052188

Group type: EXPERIMENTAL
Intervention: Text-speak SART
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Word SART
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Text-speak task (Experiment 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Word task (Experiment 2)
Number of subjects: 72
Study: 19559376

Group type: EXPERIMENTAL
Intervention: Emergency treatment for renal colic
Number of subjects: 0
Study: 17574954

Group type: EXPERIMENTAL
Intervention: Hands
Number of subjects: 36

Group type: COMPARATOR
Intervention: Device (original hard rubber tip)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Device (soft molded rubber tip)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hands (grade I to grade III mobilization)
Number of subjects: 36
Study: 16234962

Group type: EXPERIMENTAL
Intervention: Combination therapy with teriparatide plus raloxifene
Number of subjects: 137

Group type: COMPARATOR
Intervention: Teriparatide alone
Number of subjects: 137
Study: 12088118

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg/d
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 1354
Study: 10370664

Group type: EXPERIMENTAL
Intervention: HAIC (+) group (received HAIC after radical hepatectomy)
Number of subjects: 135

Group type: COMPARATOR
Intervention: HAIC (−) group (received radical hepatectomy alone)
Number of subjects: 135
Study: 7727813

Group type: EXPERIMENTAL
Intervention: Acetate free, variable chloride dialysate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard acetate containing dialysate
Number of subjects: 6
Study: 2127424

Group type: EXPERIMENTAL
Intervention: Daily x 5 bolus recombinant gamma-interferon
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous infusion x 5 days recombinant gamma-interferon
Number of subjects: 30
Study: 6995221

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: L-dopa and dopa-decarboxylase inhibitor
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31557693

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment As Usual (TAU)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 292
Study: 29099048

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) breakfast
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-carbohydrate (HC) breakfast
Number of subjects: 16
Study: 25573533

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m(2))
Number of subjects: 66
Study: 24139930

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 128
Study: 21498427

Group type: EXPERIMENTAL
Intervention: Varenicline with adherence support (AS; n = 36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Varenicline with standard care (C; n = 36)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Varenicline (both groups)
Number of subjects: 72
Study: 19376585

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Macular photocoagulation (MPC)
Number of subjects: 150
Study: 17550489

Group type: EXPERIMENTAL
Intervention: Menevit antioxidant (one capsule per day for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to Menevit, one capsule per day for three months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Menevit antioxidant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15370021

Group type: EXPERIMENTAL
Intervention: Alcohol Intervention Group (AIG) - four sessions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Alcohol Intervention Group (AIG)
Number of subjects: 34
Study: 11598393

Group type: EXPERIMENTAL
Intervention: Oral folate (5 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No vitamin supplementation (control group)
Number of subjects: 66
Study: 9688014

Group type: EXPERIMENTAL
Intervention: Continuous fluconazole at 200 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intermittent therapy at the time of symptomatic relapses
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fluconazole (up to 800 mg/day)
Number of subjects: 68
Study: 7805084

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (80 to 325 mg of aspirin) before the procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy with heparin for 1 or more days before angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended heparin therapy after thrombus or coronary dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody inhibitors to platelet membrane glycoprotein IIb/IIIa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More potent and specific antithrombin and antiplatelet agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific platelet IIb/IIIa inhibitors, hirudin, hirulog, and factor Xa inhibitors
Number of subjects: 0
Study: 2492709

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study: 338851

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Spironolactone (SP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) and Spironolactone (SP) in combination
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) and Spironolactone (SP)
Number of subjects: 79
Study: 30908472

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin as the photosensitizing agent, repeated every 3 months up to a maximum of 6 treatments.
Number of subjects: 41
Study: 31445198

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab (group A)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 5-FU/LV plus panitumumab (group B)
Number of subjects: 164
Study: 27548910

Group type: EXPERIMENTAL
Intervention: sLMA (LMA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ETT (ETT group)
Number of subjects: 40
Study: 25847900

Group type: EXPERIMENTAL
Intervention: cinacalcet in combination with potassium citrate and allopurinol
Number of subjects: 10

Group type: COMPARATOR
Intervention: potassium citrate and allopurinol (control)
Number of subjects: 10
Study: 23556995

Group type: EXPERIMENTAL
Intervention: High-Frequency Chest Wall Oscillation (HFCWO) using the Vest® Airway Clearance System
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional techniques of airway clearance (CPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy only (Control group)
Number of subjects: 30
Study: 21410125

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (150 mL of 300 mg ropivacaine, 30 mg ketorolac, and 500 μg epinephrine) with an additional 100 mg ropivacaine on postoperative day 1.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group with a single‐shot femoral nerve block (150 mg of ropivacaine with epinephrine).
Number of subjects: 83
Study: 20073306

Group type: EXPERIMENTAL
Intervention: Kirschner tension band or screw internal fixation (Group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Internal fixation of locking proximal humeral plate (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Humeral head replacement (Group C)
Number of subjects: 70
Study: 16902175

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (4x45 seconds on the Galileo 900, 30-Hz frontal plane oscillations of 3-mm amplitude, 5 days per week for 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Exercise therapy on music (same amount as whole-body vibration)
Number of subjects: 53
Study: 12782920

Group type: EXPERIMENTAL
Intervention: Ganstigmine 12.5 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ganstigmine 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ganstigmine (5, 7.5, 10 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ganstigmine (all doses)
Number of subjects: 29
Study: 11048830

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery) and Placebo
Number of subjects: 230
Study: 9091506

Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova) continued for another 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova) after 12 months of treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical tretinoin
Number of subjects: 0
Study: 8225657

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg b.i.d.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg q.d.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 3703495

Group type: EXPERIMENTAL
Intervention: Intravitreal thrombin (100 units/ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravitreal thrombin
Number of subjects: 28
Study: 31950948

Group type: EXPERIMENTAL
Intervention: GTE-CUR drink (17.3 and 35.5 mg EGCG equivalent)
Number of subjects: 0
Study: 30095451

Group type: EXPERIMENTAL
Intervention: Video-enhanced curriculum
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 49
Study: 27344985

Group type: EXPERIMENTAL
Intervention: Duration of Untreated Psychosis (DUP)
Number of subjects: 122
Study: 24561340

Group type: EXPERIMENTAL
Intervention: Fluoride releasing glass ionomer cement (GC Fuji Ortho LC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional composite (Transbond XT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both adhesive types
Number of subjects: 20
Study: 22800353

Group type: EXPERIMENTAL
Intervention: Ultracision-harmonic scalpel
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional tonsillectomy (control)
Number of subjects: 88
Study: 20169667

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC) therapy: 180 mg/m2 paclitaxel on day 1 plus AUC 6 mg/mL x minute carboplatin on day 1 every 21 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (CPT-P) therapy: 60 mg/m2 irinotecan hydrochloride on days 1, 8, 15 plus 60 mg/m2 cisplatin on day 1 every 28 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 99
Study: 18286417

Group type: EXPERIMENTAL
Intervention: Dropping flashcards as a study method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Using flashcards without dropping items
Number of subjects: 0
Study: 12573174

Group type: EXPERIMENTAL
Intervention: Accord
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eclipse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Own brand
Number of subjects: 20

Group type: COMPARATOR
Intervention: Denicotinized tobacco cigarettes
Number of subjects: 20
Study: 9726692

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination treatment (cerivastatin and nifedipine)
Number of subjects: 0